Astra Buying Bristol Makes No Sense, Fazeli Says

• Analyst Sam Fazeli sees no logical reason for AstraZeneca to acquire Bristol-Myers Squibb.
• AstraZeneca has strong double-digit growth forecasts, while Bristol-Myers faces flat or declining earnings due to patent expirations.
• The argument for increased market access is dismissed, as both are already international pharma companies with established footprints.
• Fazeli characterizes such mega-mergers as 'value destroying' and primarily driven by cost-cutting, not pipeline enhancement.

Bloomberg Intelligence analyst Sam Fazeli argues that a potential merger between AstraZeneca and Bristol-Myers Squibb makes 'no sense' for AstraZeneca. He highlights AstraZeneca's strong growth prospects versus Bristol-Myers' declining earnings due to patent expirations, suggesting the deal would dilute AZN's earnings and is value-destroying. The market reaction, with AstraZeneca shares falling, seems to align with this skepticism.